×
About 418 results

ALLMedicine™ Acquired Hemophilia Center

Research & Reviews  146 results

Management of acquired hemophilia A: results from the Spanish Registry.
https://doi.org/10.1182/bloodadvances.2021004626
Blood Advances; Mingot-Castellano ME, Pardos-Gea J et. al.

Sep 15th, 2021 - The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed-up for a median time of 12 months. Patients were predominantly male (...

Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and...
https://doi.org/10.1111/jth.15515
Journal of Thrombosis and Haemostasis : JTH; Bonnefoy A, Merlen C et. al.

Aug 30th, 2021 - Acquired hemophilia A (AHA) is a potentially life-threatening bleeding disorder caused by factor VIII (FVIII) autoantibodies, involving various immunoglobulin (Ig) isotypes and IgG subclasses. We analyzed the profile of Ig against FVIII in patient...

Feasibility of therapeutic plasma exchange-based combination therapy in the treatment o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294921
Medicine Wang LY, Shen Y et. al.

Aug 17th, 2021 - Poor availability and a lack of affordability of bypassing agents (recombinant activated factor VII and activated prothrombin complex concentrate) in west China prompted us to investigate an alternative cost-effective combination therapy. We aimed...

Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemo...
https://doi.org/10.1055/a-1579-5396
Thrombosis and Haemostasis; Farley S, Ousley R et. al.

Aug 6th, 2021 - Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemophilia A.|2021|Farley S,Ousley R,Van Wagoner N,Bril F,|

see more →

Drugs  7 results see all →

News  14 results

New consensus recommendations on bleeding in acquired hemophilia
https://www.mdedge.com/internalmedicine/article/209872/bleeding-disorders/new-consensus-recommendations-bleeding-acquired?channel=39313
Caleb Rans

Oct 10th, 2019 - New consensus statements, released by a group of 36 experts, provide specific recommendations related to monitoring bleeding and assessing efficacy of treatment in patients with acquired hemophilia. Svisio/Thinkstock A global survey was developed.

An unusual cause of bruising
https://www.mdedge.com/ccjm/article/205517/hematology/unusual-cause-bruising/page/0/1?channel=50

Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.

FVIII/W ratio may help predict relapse in hemophilia A
https://www.mdedge.com/hematology-oncology/article/201468/bleeding-disorders/fviii/w-ratio-may-help-predict-relapse?channel=27970
Caleb Rans

May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

CHMP recommends change for eptacog alfa
https://www.mdedge.com/hematology-oncology/article/184636/thrombosis/chmp-recommends-change-eptacog-alfa
HT Staff

Oct 20th, 2018 - Photo by Bill Branson Vials of drug The European Medicine’s Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the terms of the marketing authorization for the recombinant factor VIIa product eptacog alfa (N.

see more →